# Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/interim-analysis-of-post-marketing-surveillance-of-ravulizumab-for-paroxysmal/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kensuke Usuki,Takayuki Ikezoe,Ken Ishiyama,Yoshinobu Kanda,Akihiko Gotoh,Hideo Hayashi,Akihiko Shimono,Akiyo Kitajima,Naoshi Obara,Jun‐ichi Nishimura |
| Citations | 5 |
| DOI | 10.1007/s12185-023-03625-8 |
| Fields | Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4384924275 |
| PMID | 37477863 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Kensuke Usuki](https://scholariq.org/researchers/kensuke-usuki/)
- [Yoshinobu Kanda](https://scholariq.org/researchers/yoshinobu-kanda/)
- [Takayuki Ikezoe](https://scholariq.org/researchers/takayuki-ikezoe/)
- [Hideo Hayashi](https://scholariq.org/researchers/hideo-hayashi/)
- [Akihiko Shimono](https://scholariq.org/researchers/akihiko-shimono/)

## Paper funders

- [Japan Society for the Promotion of Science](https://scholariq.org/funders/japan-society-for-the-promotion-of-science/)

## Paper journal

- [International Journal of Hematology](https://scholariq.org/journals/international-journal-of-hematology/)

## Paper primary topic

- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)

## Paper topics

- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Adenosine and Purinergic Signaling](https://scholariq.org/topics/adenosine-and-purinergic-signaling/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.